Inogen, Inc · NASDAQ:INGN
Inogen — Q1 2025 Earnings Presentation
8 slides from Inogen's earnings presentation, May 7, 2025
Slide 1: Q1 2025 Supplemental Financial Information
May 7, 2025 Q1 2025 Supplemental Financial Information
Slide 2: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures Inogen has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three months ended March 31, 2025, and March 31, 2024. Management believes that non-GAAP financial measures, taken in conjunction with U.S. GAAP fin
Slide 3: Q1 2025 Results
Q1 2025 Results Revenue by region and category Total by Category Q1 2025 Revenue Year-Over-Year Change % of Total Revenue Business-to-business $21.5 million 29.9% 26.1% domestic sales Business-to-business $32.0 million 22.9% 38.9% international sales Direct-to-consumer $15.0 million (26.8)% 18.2% do
Slide 4: Operating Expense and Net Loss
Operating Expense and Net Loss (in thousands) Three months ended March 31, 2025 2024 Operating expense Research and development $ 4,034 $ 6,578 Sales and marketing 23,757 26,936 General and administrative 16,237 17,131 Total operating expense 44,028 50,645 Loss from operations (7,656) (16,274) Other
Slide 5: Reconciliation of GAAP to Non-GAAP: Adjusted EBITDA
Reconciliation of GAAP to Non-GAAP Adjusted EBITDA (in thousands) Three months ended March 31, Non-GAAP EBITDA and Adjusted EBITDA 2025 2024 Net loss (GAAP) $ (6,174) $ (14,578) Non-GAAP adjustments: Interest income, net (1,029) (1,403) Benefit for income taxes (97) (150) Depreciation and amortizati
Slide 6: Reconciliation of GAAP to Non-GAAP: Adjusted Net Loss
Reconciliation of GAAP to Non-GAAP Adjusted Net Loss (in thousands) Three months ended March 31, Operating Expense Loss from Operations Net Loss Diluted EPS Non-GAAP Financial Metrics 2025 2024 2025 2024 2025 2024 2025 2024 Financial Results (GAAP) $ 44,028 $ 50,645 $ (7,656) $ (16,274) $ (6,174) $
Slide 7: Stock-Based Compensation
Stock-Based Compensation (in thousands) Three months ended March 31, 2025 2024 Stock-based compensation expense by type of award: Restricted stock units and restricted stock awards $ 2,008 $ 2,309 Employee stock purchase plan 139 107 Total stock-based compensation expense $ 2,147 $ 2,416 Three month
Slide 8: Improving lives through respiratory care
Improving lives through respiratory care